ImmVirX receives $2.81M R&D tax refund for FY22
ImmVirX receives $2.81M R&D tax refund for FY22 Melbourne, Australia 28 November 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $2,813,837 Research and Development (R&D) tax refund […]
